EGI
ASMB icon

EAM Global Investors’s Assembly Biosciences ASMB Stock Holding History

EAM Global Investors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,995
Closed -$1.18M – 155
2018
Q1 		$1.18M Sell
1,995
-258
-11% -$160K 0.61% 75
2017
Q4 		$1.22M Buy
+2,253
New +$1.02M 0.63% 41

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Global Investors's ASMB Position: Q2 2018 in Review

EAM Global Investors sold out of Assembly Biosciences (ASMB) in Q2 2018, closing a stake of 1,995 shares — an estimated $1.18M sold.

EAM Global Investors first reported a position in ASMB in Q4 2017 and held it in 2 quarters. The position peaked at $1.22M in Q4 2017. 105 funds tracked by Wall St. Rank hold ASMB as of Q2 2018.

  • EAM Global Investors reported no remaining Assembly Biosciences position as of Q2 2018 after selling out during the quarter.
  • EAM Global Investors sold 1,995 Assembly Biosciences shares in Q2 2018, an estimated $1.18M.
  • EAM Global Investors first reported a position in Assembly Biosciences in Q4 2017 and held it in 2 quarters.
  • EAM Global Investors's Assembly Biosciences position peaked at $1.22M in Q4 2017.
  • 105 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2018.

Based on EAM Global Investors's 13F filing for Q2 2018, filed 3 Aug 2018.